Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Troplasminogen alfa

Next Previous
X
Search
Drug Profile

Troplasminogen alfa

Alternative Names: BB-10153; Tapgen; V-10153

Latest Information Update: 09 Apr 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Class Anti-ischaemics; Antiarrhythmics; Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 25 Aug 2015 Discontinued - Phase-II for Stroke in USA, Canada, Czech Republic, Denmark and Hungary (IV)
  • 12 Nov 2010 V 10153 is available for licensing in World as of 28 Feb 2000. http://www.vernalis.com/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top